Application of FMD Type O Antibody ELISA in Post-Vaccination Monitoring and Herd Immunity Assessment

Foot-and-mouth disease virus (FMDV) serotype O remains the dominant lineage in many regions. Post-vaccination monitoring (PVM) requires high-throughput, validated serological assays to quantify seroconversion and infer population-level protection. This article details how Type O structural-protein ELISAs (LPBE/SPCE formats) and NSP (3ABC) ELISAs are applied within science-based surveillance frameworks, how to set decision thresholds using ROC methods, and how to translate individual titers into herd immunity estimates using $1-1/R_0$ adjusted for vaccine effectiveness. Guidance aligns with government contingency plans and bioanalytical method standards.

Keywords (SEO): FMD Type O ELISA, LPBE, SPCE, 3ABC NSP ELISA, DIVA, virus neutralization test, r1-value, post-vaccination monitoring, herd immunity threshold, ROC/AUC, Epi Info sample size, USDA APHIS Red Book, CFSPH, NVSL FADDL.

1) Regulatory & programmatic context for PVM

Robust PVM is embedded in official control strategies and emergency response plans. For operational frameworks, assay choices and sampling designs should align with:

• USDA APHIS FMD Response Plan (“Red Book”) (diagnostics, surveillance, vaccination and decision workflows). APHIS Red Book PDF, Ready-Reference overview, and diagnostics RRG (flows after confirmation). Diagnostics RRG. APHIS+2APHIS+2

• GOV.UK national FMD control strategy and notifiable disease procedures (useful templates for surveillance objectives and reporting). GB FMD control strategy, How to spot/report FMD. GOV.UK+1

• CFSPH (Iowa State University) technical factsheets and vaccination appendices covering the roles of structural-protein (SP) and non-structural-protein (NSP) serology in outbreaks. CFSPH FMD factsheet, NAHEMS Vaccination Appendix (CFSPH). CFSPH+1

2) Assay portfolio for PVM: Type O SP-ELISA, VNT, and NSP-ELISA (DIVA)

2.1 Structural-protein (SP) Type O antibody ELISA

For serotype-specific vaccine response, laboratories typically deploy LPBE (liquid-phase blocking ELISA) and/or SPCE (solid-phase competitive ELISA) configured with Type O antigens/monoclonals. These assays quantify total anti-capsid antibodies elicited by vaccine or infection and are suited to high-throughput PVM. Evidence from academic and government labs supports SPCE/LPBE for Type O monitoring and vaccine matching studies. See e.g., Pirbright evaluations (LPBE/SPCE vs VNT) and vaccine matching work. Pirbright evaluation (LPBE/SPCE/VNT), Vaccine matching & LPBE. pirbright.ac.uk+1

Operational note: U.S. national reference capacity at NVSL/FADDL (Plum Island) lists FMD Ag ELISA, VN (per serotype, including O), and 3ABC ELISA for NSPs as routine diagnostics—confirming availability and regulatory acceptance of these modalities during responses. NVSL/FADDL diagnostic testing catalog. APHIS

2.2 Virus neutralization test (VNT) for correlation / protection inference

VNT remains a reference for functional neutralizing activity and often anchors ELISA cutoff optimization. It is listed and used by national labs in FMD programs. NVSL/FADDL catalog (VN per serotype), [APHIS Red Book references to structural-protein assays incl. SPCE]. APHIS+1

2.3 NSP (3ABC) ELISA for DIVA

To distinguish infection from vaccination (DIVA) in vaccinated populations, anti-NSP assays (e.g., 3ABC ELISA) are required in parallel with SP ELISAs. Both APHIS and CFSPH documents specify roles for NSP ELISA in surveillance/PVM. NVSL 3ABC ELISA listing, NAHEMS Vaccination Appendix (APHIS/CFSPH). APHIS+1

3) Method validation & analytical performance (precision, specificity, sensitivity)

For laboratory accreditation and cross-study comparability, apply FDA ICH M10 bioanalytical method validation principles to ELISAs: calibration model, accuracy/precision, selectivity, parallelism/linearity, LLOQ/ULOQ, stability, and incurred sample reanalysis where appropriate. While M10 targets pharmacokinetic ligand-binding assays, its criteria are directly applicable to ELISA performance. See: FDA M10 guidance (final, Nov-2022) and FDA Bioanalytical Method Validation guidance. U.S. Food and Drug Administration+1

For assay-format background and SOP-level details on ELISA execution (plate blocking, curve fitting, QC), see university resources: UAB ELISA manual, OHSU ELISA slides.

NSP ELISA developments and competitive formats (e.g., anti-3B/3ABC) are documented by U.S. government research programs. USDA-ARS publications on cELISA/NSP, GFRA gap analysis citing 3ABC ELISAs. ARS+1

4) Determining ELISA decision thresholds (cutoffs) with ROC analysis

A scientifically defensible Type O ELISA cutoff should be derived by ROC analysis vs. a reference (e.g., VNT), optimizing sensitivity/specificity for the PVM decision (e.g., seropositive above protection surrogate). Implement ROC/AUC and Youden’s J with standard academic methods: Penn State STAT 504 ROC tutorial, Cornell CSCU ROC guide, NIST ITL notes. PennState: Statistics Online CoursesCSCUNIST

5) Translating serology into herd immunity estimates

Use the classical herd-immunity threshold (HIT) derived from the basic reproduction number $R_0$, adjusting for vaccine effectiveness ($VE$):

$$HIT \approx \frac{1-1/R_0}{VE}$$

• CDC/NIH educational materials document $HIT = 1 – 1/R_0$ and its use in vaccination planning. CDC stacks example, NIH/PMC explainer.

• Government FMD sources indicate effective reproduction numbers for FMD often $\lesssim 4$ in vaccinated/control settings (context-dependent by species, husbandry, and biosecurity). USDA-ARS R₀ notes for FMD.

Worked example (planning): If local modeling/experience suggests $R_0=3$ and field VE=0.80, then $HIT \approx (1-1/3)/0.80 = 0.667/0.80 \approx 0.83$. You would target ≥ 83% of animals with Type O ELISA titers above the validated cutoff to sustain herd immunity between campaigns. stacks.cdc.govPMCARS

6) Sampling design, sample size & representativeness for PVM

• Stratification. Sample by species/age/production unit and vaccination history (primary vs booster) with clustering accounted at herd level.

• Sample size. Use CDC Epi Info™ StatCalc to size cross-sectional surveys for expected seroprevalence and desired precision/power. Epi Info StatCalc intro, Population survey sample size, Windows downloads. CDC+2CDC+2

• Timing. Draw windows consistent with kinetics of humoral response post-vaccination and program guidance in contingency plans (pair SP-ELISA for seroconversion with NSP ELISA to exclude breakthrough infection). NAHEMS Vaccination Appendix (APHIS/CFSPH), CFSPH PVM use of serology. APHISCFSPH

7) Vaccine matching & interpreting Type O serology

To confirm that the deployed Type O vaccine antigenically covers circulating field strains, labs combine serology with vaccine matching metrics (e.g., r1-values), often using VNT/ELISA data. Values >0.3 are typically interpreted as a close antigenic relationship. Integrate these data with titers to prioritize booster intervals and vaccine selection. GFRA/USDA r1 value guidance, Pirbright field apps with LPBE/VNT. ARSpirbright.ac.uk

8) Data management, QA/QC and reporting

• QA/QC: Implement calibrators/controls per FDA M10; lock analysis plans (curve-fit, weighting, acceptance criteria), and track drift with Westgard-type rules. FDA M10 PDF. U.S. Food and Drug Administration

• Result integration: Report individual outcomes (SP-ELISA titer/OD% inhibition; NSP status) and herd-level seroprevalence with 95% CIs.

• Regulatory reporting: Maintain awareness of notifiable disease obligations—UK reporting, Canada CFIA, NZ MPI—especially when NSP seropositivity indicates possible exposure. GOV.UK FMD guidance, CFIA FMD, MPI NZ FMD. GOV.UKACIAMinistère des Industries Primaires

9) Practical PVM pipeline for Type O vaccination programs

1. Define objectives (e.g., ≥ 80–85% seropositive above cutoff in target cohorts) based on local $R_0$ estimates and vaccine VE. USDA-ARS on $R_0$. ARS

2. Choose assays:

   • Type O SP-ELISA (LPBE/SPCE) for vaccine response quantification.

   • NSP 3ABC ELISA for DIVA.

   • VNT subset for cutoff verification and antigenic matching. NVSL/FADDL test catalog. APHIS

3. Validate/verify performance locally under M10 principles; document accuracy/precision/LLOQ/parallelism. FDA M10. U.S. Food and Drug Administration

4. Power the survey and stratify; compute sample size in Epi Info StatCalc. CDC StatCalc. CDC

5. Analyze with ROC (per-cohort cutoff confirmation), then estimate seroprevalence and HIT attainment. PSU ROC, Cornell ROC. PennState: Statistics Online CoursesCSCU

6. Escalate NSP-positives and below-cutoff clusters per national SOPs (see APHIS diagnostics RRG & GOV.UK control strategy). APHIS Diagnostics RRG, GB control strategy. APHISGOV.UK

10) Authoritative references for further implementation

• Program & disease control: APHIS Red Book, APHIS RRG (surveillance/diagnostics), GOV.UK latest situation. APHIS+1GOV.UK

• Assays: NVSL/FADDL test menu (Ag ELISA, SP/VN, NSP 3ABC). APHIS

• University technicals: CFSPH FMD factsheet (ISU), UAB ELISA manual, PSU ROC, Cornell ROC. CFSPHvaccine.uab.eduPennState: Statistics Online CoursesCSCU

• Modeling & herd immunity: CDC/NIH herd-immunity formula examples, USDA-ARS FMD $R_0$ note. stacks.cdc.govARS

Compliance reminder (programmatic)

• Notifiable disease rules may mandate immediate reporting of suspect infection (e.g., NSP-positive clusters). See GOV.UK notifiable disease collection, CFIA procedures, NZ MPI readiness. GOV.UK notifiable diseases, CFIA FMD, MPI FMD readiness. GOV.UKACIAMinistère des Industries Primaires

Appendix: Quick, reproducible setup (labs & programs)

• Assay selection: Type O LPBE or SPCE for SP antibodies; 3ABC NSP ELISA for DIVA; VNT subset calibration—confirmed as available at NVSL/FADDL. NVSL/FADDL catalog. APHIS

• Validation: execute M10-aligned plans (selectivity, precision, LLOQ/ULOQ, stability, ISR). FDA M10. U.S. Food and Drug Administration

• Survey sizing: Epi Info™ StatCalc (cross-sectional), prespecify precision and design effect; oversample youngstock/primary-vaccinees. CDC StatCalc. CDC

• Analysis: ROC/AUC for cutoffs; seroprevalence with 95% CIs; compute HIT using locally justified $R_0$ and field VE. PSU ROC, CDC herd-immunity demonstration. PennState: Statistics Online Coursesstacks.cdc.gov

Additional government/academic resources (for depth)

• USDA-ARS timeline on FMD countermeasures (vaccine surge/readiness). ARS timeline. ARS

• CFIA overview & factsheets (Canada). CFIA FMD overview, CFIA fact sheet. ACIA+1

• NZ MPI FMD pages (programmatic readiness). About FMD. Ministère des Industries Primaires